Therapeutic Strategies Targeting HER2 for Gastric Cancer
HER2-positive gastric cancer accounts for 30-40% of gastric cancer patients. Since the ToGA trial, trastuzumab has become the mainstay of first-line therapy for HER2-positive gastric cancer over the past decade. Antibody-drug conjugate (ADC)has created a new treatment option recently. The combination and sequence of these anti-HER2 agents with the immune checkpoint inhibitors is reported to be promising. In this article, we review the major clinical trials and discuss the prospects and challenges of treatment strategy for HER2-positive gastric cancer.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
---|---|
Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 50(2023), 7 vom: 02. Juli, Seite 756-762 |
Sprache: |
Japanisch |
---|
Beteiligte Personen: |
Baba, Keisuke [VerfasserIn] |
---|
Themen: |
EC 2.7.10.1 |
---|
Anmerkungen: |
Date Completed 28.07.2023 Date Revised 28.07.2023 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM359962238 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359962238 | ||
003 | DE-627 | ||
005 | 20231226082006.0 | ||
007 | tu | ||
008 | 231226s2023 xx ||||| 00| ||jpn c | ||
028 | 5 | 2 | |a pubmed24n1199.xml |
035 | |a (DE-627)NLM359962238 | ||
035 | |a (NLM)37496216 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a jpn | ||
100 | 1 | |a Baba, Keisuke |e verfasserin |4 aut | |
245 | 1 | 0 | |a Therapeutic Strategies Targeting HER2 for Gastric Cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 28.07.2023 | ||
500 | |a Date Revised 28.07.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a HER2-positive gastric cancer accounts for 30-40% of gastric cancer patients. Since the ToGA trial, trastuzumab has become the mainstay of first-line therapy for HER2-positive gastric cancer over the past decade. Antibody-drug conjugate (ADC)has created a new treatment option recently. The combination and sequence of these anti-HER2 agents with the immune checkpoint inhibitors is reported to be promising. In this article, we review the major clinical trials and discuss the prospects and challenges of treatment strategy for HER2-positive gastric cancer | ||
650 | 4 | |a Review | |
650 | 4 | |a English Abstract | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Trastuzumab |2 NLM | |
650 | 7 | |a P188ANX8CK |2 NLM | |
700 | 1 | |a Boku, Narikazu |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 50(2023), 7 vom: 02. Juli, Seite 756-762 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
773 | 1 | 8 | |g volume:50 |g year:2023 |g number:7 |g day:02 |g month:07 |g pages:756-762 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 50 |j 2023 |e 7 |b 02 |c 07 |h 756-762 |